Five things for pharma marketers to know: Monday, September 26, 2016

1. Pfizer announced that it will not split into two companies because doing so is not expected to bring shareholder value. The drugmaker had publicly discussed the possibility of splitting the company for years. (Reuters)

2. Merck's immunotherapy cancer drug Keytruda has seized an advantage over its competitor, Bristol-Myers Squibb's Opdivo, in China: It will be imported as part of a medical tourism program in Hainan, a resort island. The program seeks to attract patients who would instead go to Hong Kong or Macau for treatment. (WSJ)

3. Apple's HealthKit will likely be used to do more than collect fitness data, sources told Bloomberg. The company may develop software to interpret data collected from its devices to better understand how to treat patients. (Bloomberg)

4. The FDA approved Amgen's Amjevita, the first biosimilar of AbbVie's best-selling inflammatory drug Humira. Amjevita becomes the fourth biosimilar approved in the U.S. (MM&M)

5. Dupilumab, an experimental eczema drug developed by Sanofi and Regeneron Pharmaceuticals, may be approved by the FDA by March. Analysts believe the drug has the potential to generate up to $3 billion a year in sales. (Reuters)